The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.
IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.
IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.
The latest report by IMARC, titled “ Anticoagulants Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2 028
” finds that the global anticoagulants market reached a value of US$ 37.4 Billion in 2022.
Anticoagulants, also known as blood thinners, are chemical substances that prevent or reduce the coagulation of blood and extend the blood clotting time. They are utilized to minimize the risk of blood clots in various medical conditions, such as myocardial infarction, deep vein thrombosis, pulmonary embolism, and stroke.
These drugs are usually available in capsule or tablet form, including warfarin, rivaroxaban, dabigatran, and apixaban. Owing to these properties, doctors widely prescribe anticoagulants to people who are at a high risk of clot formation.
Request Free Sample Report: https://www.imarcgroup.com/anticoagulants-market/requestsample
The market is primarily driven by the rising incidences of hypercoagulability across the globe. In addition, the growing prevalence of human immunodeficiency virus (HIV), hepatitis C, Lyme disease, obesity, cancer, and chronic inflammation, represents another major growth-inducing factor. Besides this, extended sitting, smoking, trauma, blood disorders, and autoimmune diseases can cause blood clotting in different parts of the body.
This, coupled with the improving diagnosis rates and the rising adoption of target therapeutics, is positively influencing the market growth. Furthermore, the surging number of surgeries requiring prolonged bed rest also increases the risk of blood clots among individuals, thus propelling the market growth. Looking forward, IMARC Group expects the market to reach a value of US$ 67.0 Billion by 2028, exhibiting a CAGR of 10.1% during the forecast period (2023-2028).
Looking forward, the market value is projected to reach a strong growth during the forecast period (2023-2028).
Market Summary:
Drug Class Insights:
• Novel Oral Anticoagulants (NOACs)
• Heparin and Low Molecular Weight Heparin (LMWH)
• Vitamin K Antagonist
• Others
Route of Administration Insights:
• Oral Anticoagulant
• Injectable Anticoagulant
Distribution Channel Insights:
• Hospital Pharmacies
• Retail Pharmacies
• Online Stores
• Others
Application Insights:
• Atrial Fibrillation and Heart Attack
• Stroke
• Deep Vein Thrombosis (DVT)
• Pulmonary Embolism (PE)
• Others
Regional Insights:
• North America
• United States
• Canada
• Asia-Pacific
• China
• Japan
• India
• South Korea
• Australia
• Indonesia
• Others
• Europe
• Germany
• France
• United Kingdom
• Italy
• Spain
• Russia
• Others
• Latin America
• Brazil
• Mexico
• Others
• Middle East and Africa
Competitive Landscape with Key Players:
• Alexion Pharmaceuticals Inc
• Aspen Holdings
• Bayer AG
• Boehringer Ingelheim International GmbH
• Bristol-Myers Squibb Company
• Daiichi Sankyo Company Limited
• Dr. Reddy’s Laboratories Ltd
• GlaxoSmithKline plc
• Johnson & Johnson Private Limited
• Pfizer Inc.
• Sanofi
We are the trusted business partners to the world's leading corporates, governments, and institutions
We are the trusted business partners to the world's leading corporates, governments, and institutions
© 2019 IMARC All Rights Reserved
This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).
Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.
IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.
